Monoclonal Antibodies
Developed to prevent and improve treatment of infectious diseases.
Lead Candidate
Monoclonal antibodies directed against M. Tuberculosis.
Monoclonal antibodies (MABs) directed against M. tuberculosis (MTB) not only promote macrophage opsonophagocytic killing activity (OPKA), but also enhance blood clearance of MTB and may improve treatment of multiple drug resistant and extensively drug resistant (MDR/XDR) TB. The target identified also crosses gram positive bacteria. Combined with two other identified targets, the MAB cocktail could be a potent weapon in treating sepsis.
Research
-
Opsonic Monoclonal Antibodies Directed Against MTB Enhance Blood Clearance in a Quantitative qPCR Mouse Model
-
Antibody Mediated Killing of Mycobacteria by Macrophage Cells Correlates with In Vivo Blood Clearance of Mycobacterium Tuberculosis
-
A novel monoclonal antibody enhances phagocytosis and killing of Mycobacterium Tuberculosis in macrophage cells
-
Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies
